title: Long-term outcome of hypofractionated radiotherapy to the whole breast of Japanese women after breast-conserving surgery.
abstract: BACKGROUND
  In Japan, there are still no reports of long-term outcome for hypofractionated radiotherapy to the whole breast after breast-conserving surgery (BCS). We report our institution's results from evaluation of the efficacy and safety of hypofractionated radiotherapy for Japanese women.
  
  
  METHODS
  Data in the medical records of 327 patients were retrospectively reviewed. The patients were treated with hypofractionated radiotherapy between January 2003 and December 2006 at the Kawasaki Medical School Hospital and were followed for more than 3 years. The median age was 54 years old (the age range was 28-80 years). The whole breast was irradiated with a total dose of 42.56 Gy/16 fx with boost irradiation to positive margins. Adjuvant therapy consisted of chemotherapy and/or hormone therapy and was administered to 300 patients, based on their stage or pathological findings.
  
  
  RESULTS
  Follow-up periods ranged from 21 to 92 months; the median follow-up period was 60 months. At 5-year follow-up, overall survival, cause-specific survival, relapse-free survival, and local control were 96.0, 97.5, 95.3, and 99.7% respectively. Grade 2 radiation pneumonitis occurred in five patients. Grade 2 radiation dermatitis occurred in 17 patients. Severe late complications were not observed.
  
  
  CONCLUSIONS
  In our study, hypofractionated radiotherapy led to good results without severe toxicity. We believe hypofractionated radiotherapy after BCS is safe and efficient treatment for Japanese women.
authors.affiliation: Department of Radiation Oncology, Kawasaki Medical School, 577, Matsushima, Kurashiki, Okayama, 701-0192, Japan, spz694w9@onyx.ocn.ne.jp.
authors.forename: Takeaki
authors.initials: T
authors.lastname: Ishihara
authors.forename: Eisaku
authors.initials: E
authors.lastname: Yoden
authors.forename: Kei
authors.initials: K
authors.lastname: Konishi
authors.forename: Naomi
authors.initials: N
authors.lastname: Nagase
authors.forename: Kenji
authors.initials: K
authors.lastname: Yoshida
authors.forename: Junichi
authors.initials: J
authors.lastname: Kurebayashi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sonoo
authors.forename: Nobutaka
authors.initials: N
authors.lastname: Murashima
authors.forename: Ryohei
authors.initials: R
authors.lastname: Sasaki
authors.forename: Junichi
authors.initials: J
authors.lastname: Hiratsuka
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D044466:Asian People; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D019583:Dose Fractionation, Radiation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015412:Mastectomy, Segmental; D008875:Middle Aged; D011855:Radiodermatitis / Q000209:etiology; D011878:Radiotherapy / Q000009:adverse effects; D012189:Retrospective Studies; D016896:Treatment Outcome